Device Trial Radar · NCT06418880
Automated Insulin Delivery for Inpatients With Dysglycemia
Last checked: Nov 20, 2026Latest source record: Nov 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Jan 22, 2025
Primary completion
Oct 31, 2025
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- May 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized controlled trial will test the efficacy and safety of automated insulin delivery (AID) in hospitalized patients with diabetes (type 1 or type 2) requiring insulin therapy who are admitted to general medical/surgical floors. The main objectives of this study are: * To test the efficacy and safety of AID versus multiple daily insulin injections (MDI) + CGM in the inpatient setting * To determine differences in CGM-derived metrics between AID and MDI plus CGM in the hospital and explore differences in treatment effect according to individual characteristics. Participants will be: * Randomized to AID + remote CGM (intervention) or multiple daily insulin injections (MDI) + CGM (control group) * Followed for a total of 10 days or until hospital discharge (if less than 10 days).
Conditions
- Type 1 Diabetes
- Type 2 Diabetes
Interventions
AID system with Remote Real-Time CGMDevice
The Omnipod 5 AID System is comprised of two components: * Omnipod 5 Pod (insulin infusion pump with SmartAdjust technology) * Omnipod 5 App (installed on the Controller or smart phone) The Omnipod 5 AID pod is a lightweight, self-adhesive device that the user fills with U-100 rapid-acting insulin and wears directly on their body. The Pod delivers insulin into the user's body through a small flexible tube, called a cannula, based on the commands from the compatible Controller. In the Omnipod 5 AID System, the Pod itself houses the MPC algorithm and communicates directly with the CGM and the Omnipod 5 App. Based on predicted glucose values, the algorithm commands the Pod's insulin delivery through micro-boluses.
Standard of Care Insulin Therapy + CGMCombination product
This includes the usage of subcutaneous insulin for glucose control. Participants will wear a real-time Continuous Monitoring (CGM) for 10 days or until hospital discharge (if \<10 days). Treatment decisions will be based on POC testing with consideration of daily evaluation of CGM patterns.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy: Time spent in glucose target rangeTime frame: Up to 10 days (or hospital discharge if before 10 days)
- Safety: Time spent below the target glucose rangeTime frame: Up to 10 days (or hospital discharge if before 10 days)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Stanford University School of Medicine
Stanford, California
Grady Health System (non-CRN)
Atlanta, Georgia
University of Virginia School of Medicine
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.